Literature DB >> 18558429

The placenta contributes to activation of the renin angiotensin system in twin-twin transfusion syndrome.

P Galea1, O Barigye, L Wee, V Jain, M Sullivan, N M Fisk.   

Abstract

The renin-angiotensin system (RAS) in twin-twin transfusion syndrome (TTTS) is up-regulated in the donor fetus's kidneys, but down-regulated in the recipient's. Ultrasonographic and echocardiographic features suggest that the recipient is also exposed to RAS components. In this study we investigated the role and origin of RAS components in the recipient fetus. Monochorionic diamniotic (MCDA) pregnancies were recruited from a tertiary fetal medicine service. Cord blood was collected from MCDA twins (TTTS and control non-TTTS) at delivery for renin and angiotensin II immunoassays. Placental tissue was flash-frozen for mRNA and protein expression or formalin-fixed for immunohistochemistry. Archival placenta and kidney samples were used for immunohistochemistry and in-situ hybridization. Plasma renin levels were elevated (p<0.05) in recipients (median 201 pg/ml, range 54-315 pg/ml) and donors (125 pg/ml, 25-296) with TTTS compared to controls (2.5 pg/ml, 1.1-1.5 pg/ml). The same was found with angiotensin II with high levels in both recipients (300.5 pg/ml, 86.1-488 pg/ml) and donors (239 pg/ml, 76.6-422) compared to controls (169.5 pg/ml, 89-220 pg/ml, p<0.05). Renin mRNA expression, and protein appeared qualitatively higher in the placental territory of the recipient compared to that of the donor and non-TTTS controls. We conclude that both fetuses in TTTS are exposed to high levels of RAS components; these appear to be produced from different sites, namely the kidney of the donor, and the placenta of the recipient. Given the markedly different phenotypes in the genetically identical fetuses with TTTS, we suggest that the source of RAS components may influence their clinical manifestations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558429     DOI: 10.1016/j.placenta.2008.04.010

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  9 in total

1.  Minimally invasive fetoscopic interventions: an overview in 2010.

Authors:  Thomas Kohl
Journal:  Surg Endosc       Date:  2010-03-17       Impact factor: 4.584

2.  Renal functional markers in extremely premature infants with and without twin-twin transfusion syndrome.

Authors:  Julie Sommer; Anne-Monique Nuyt; François Audibert; Véronique Dorval; Sandrine Wavrant; Anie Lapointe; Gabriel Altit
Journal:  J Perinatol       Date:  2019-10-15       Impact factor: 2.521

3.  Chronic kidney disease following twin-to-twin transfusion syndrome-long-term outcomes.

Authors:  Nabil Ziad Melhem; Sarah Ledermann; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2018-12-17       Impact factor: 3.714

Review 4.  Diagnosis and management of heart failure in the fetus.

Authors:  B Davey; A Szwast; J Rychik
Journal:  Minerva Pediatr       Date:  2012-10       Impact factor: 1.312

5.  Overview and Long-term Outcomes of Patients Born With Twin-to-Twin Transfusion Syndrome.

Authors:  Stephen Wagner; John T Repke; Serdar H Ural
Journal:  Rev Obstet Gynecol       Date:  2013

Review 6.  Twin to twin transfusion syndrome.

Authors:  Jena L Miller
Journal:  Transl Pediatr       Date:  2021-05

Review 7.  Fetal cardiovascular alterations in twin-to-twin transfusion syndrome.

Authors:  Ioana Cristina Rotar; Gabriela Zaharie; Adelina Staicu; Andreia Preda; Daniel Mureşan
Journal:  Med Pharm Rep       Date:  2020-01-31

8.  Maternal Complications and Hemodynamic Changes Following Intrauterine Interventions for Twin-to-Twin Transfusion Syndrome in Monochorionic Diamniotic Twin Pregnancies.

Authors:  Patrick Greimel; Angela Zenz; Bence Csapó; Martin Haeusler; Uwe Lang; Philipp Klaritsch
Journal:  J Clin Med       Date:  2019-05-02       Impact factor: 4.241

9.  Twin-twin transfusion syndrome: don't rely on fluids and bladders to catch it early.

Authors:  C Wohlmuth; H M Gardiner
Journal:  Ultrasound Obstet Gynecol       Date:  2022-01       Impact factor: 8.678

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.